Remdesivir and standard care vs placebo or usual care
All‐cause mortality at up to day 281 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 281 compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
- RR 0.93 [0.81, 1.06]4 studies · 7142 participantsModerate